The review and comparative analysis of modern updated recommendations on tactics of treatment of patients with non-valve fibrillation of atrium

Abstract

The article presents comparative analysis of modern national recommendations on management of patients with non-valve form of fibrillation of atrium with European and American recommendations. The Russian and foreign approaches are compared both to anti-arrhythmic therapy and to prevention of the most threatening complication of fibrillation of atrium - acute disorder of cerebral circulation. The important differences concern the tactics of separation of most threatened patients and application of means of prevention first of all warfarin and new oral anticoagulants.

Keywords

fibrillation of atrium / clinical recommendations / warfarin / oral anticoagulant / anti-arrhythmic therapy / risk stratification

References

[1] Сулимов В.А., Явелов И.С., Панченко Е.П. и др. Выпуск № 2. Диагностика и лечение фибрилляции предсердий. Рекомендации ВНОК и ВНОА. М.; 2012.

[2] Camm A.J., Lip G.Y., De Caterina R., Savelieva I., Atar D., Hohnloser S.H. et al. Focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Europace. 2012; 14: 1385-413.

[3] Anderson J.L., Halperin J.L., Albert N.M., Bozkurt B., Brindis R.G., Curtis L.H. et al. Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS guideline recommendations: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013; 127: 1916-26.

[4] Fuster V., Ryden L.E., Cannom D.S. et al. ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). Circulation. 2006; 114: e257-354.

[5] ACCF/AHA Task Force on Practice Guidelines. Methodologies and policies from the ACCF/AHA Task Force on Practice Guidelines. Available at: http://assets.cardiosource.com/Methodology_Manual_forACC_AHA_Writing_Committees.pdf. Accessed July 2, 2010.

[6] Оганов Р.Г., Сулимов В.А., Бокерия Л.А. и др. Клинические рекомендации по диагностике и лечению пациентов с фибрилляцией предсердий. Вестник аритмологии. 2010; 59: 53-77.

[7] Сулимов В.А., Явелов И.С., Панченко Е.П. и др. Диагностика и лечение фибрилляции предсердий. Рекомендации ВНОК и ВНОА. М.; 2011.

[8] Camm A.J., Kirchhof P., Lip G.Y., Schotten U., Savelieva I., Ernst S. et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace. 2010; 12: 1360-420.

[9] Рекомендации ВНОА по проведению электрофизиологических исследований, катетерной абляции и применению имплантируемых антиаритмических устройств. М.: Всероссийское Научное Общество специалистов по клинической электрофизиологии, аритмологии и кардиостимуляции; 2013.

[10] Camm A.J., Corbucci G., Padeletti L. Usefulness of continuous electrocardiographic monitoring for atrial fibrillation. Am. J. Cardiol. 2012; 110: 270-6.

[11] Go A.S., Hylek E.M., Chang Y. et al. Anticoagulation Therapy for Stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice. JAMA. 2003; 290: 2685-92.

[12] Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann. Intern. Med. 2007; 146: 857-67.

[13] Connolly S.J., Ezekowitz M.D., Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 2009; 361: 1139-51.

[14] Ezekowitz M.D., Walentine L., Connolly S. et al. Dabigatran and Warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation. Circulation. 2010; 122: 2246-53.

[15] Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann. Intern. Med. 2007; 146: 857-67.

[16] Van Staa T.P., Setakis E., Di Tanna G.L., Lane D.A., Lip G.Y. A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice. J. Thromb. Haemost. 2011; 9: 39-48.

[17] Mosquera L., Sanchez Loureiro M., Caneda Villar M.C., Fernandez Villaverde J.M., Maestro Saavedra F.J., Gonzalez-Juanatey J.R. Оn behalf of Grupo Barbanza researchers. Comparison of the reliability and validity of four contemporary risk stratification schemes to predict thromboembolism in non-anticoagulated patients with atrial fibrillation. Int. J. Cardiol. 2011; November.

[18] Lip G.Y. The role of aspirin for stroke prevention in atrial fibrillation. Nat. Rev. Cardiol. 2011; 8: 602-6.

[19] Olesen J.B., Lip G.Y., Lindhardsen J., Lane D.A., Ahlehoff O., Hansen M.L. et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a ‘real world’ nationwide cohort study. Thromb. Haemost. 2011; 106: 739-49.

[20] Mant J., Hobbs F.D., Fletcher K. et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial.Lancet. 2007; 370: 493-503.

[21] Heidbuchel H., Verhamme P., Alings M. et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. European Society of Cardiology (ESC). Europace. 2013; 12: 1360-420.

RIGHTS & PERMISSIONS

Eco-Vector